Valuation: Sanofi

Capitalization 90.26B 105B 82.68B 78.13B 144B 10,131B 148B 985B 384B 4,769B 393B 384B 16,654B P/E ratio 2026 *
11x
P/E ratio 2027 * 10.1x
Enterprise value 103B 119B 93.91B 88.74B 164B 11,508B 168B 1,119B 436B 5,417B 446B 437B 18,917B EV / Sales 2026 *
2.19x
EV / Sales 2027 * 2.03x
Free-Float
88.31%
Yield 2026 *
5.7%
Yield 2027 * 6.01%
1 day+1.81%
1 week+5.28%
Current month-4.08%
1 month-6.67%
3 months-3.79%
6 months-10.27%
Current year-7.45%
1 week 72.61
Extreme 72.61
76.61
1 month 71.73
Extreme 71.73
84.04
Current year 71.73
Extreme 71.73
84.97
1 year 71.73
Extreme 71.73
94.07
3 years 71.73
Extreme 71.73
110.88
5 years 71.73
Extreme 71.73
110.88
10 years 62.5
Extreme 62.5
110.88
Manager TitleAgeSince
Chief Executive Officer 64 2026-04-30
Director of Finance/CFO 64 2024-03-31
Chief Tech/Sci/R&D Officer 51 2023-09-10
Director TitleAgeSince
Director/Board Member 60 2019-04-29
Director/Board Member 56 2020-04-27
Director/Board Member 64 2020-04-27
Change 5d. change 1-year change 3-years change Capi.($)
+1.81%+5.28%-18.14%-23.67% 105B
+3.37%+3.19%+35.27%+130.89% 911B
+0.47%+2.56%+50.83%+44.74% 554B
+2.08%+2.84%+15.10%+47.31% 378B
+1.47%+0.40%+24.15%+11.99% 333B
+0.06%+0.99%+33.44%+15.50% 288B
+0.29%+2.23%+27.99%+30.86% 287B
+1.49%+1.66%+47.92%-1.08% 282B
-0.03%-4.04%-37.06%-51.33% 198B
+1.96%-1.65%+19.90%+48.04% 179B
Average +0.52%+1.49%+19.94%+25.32% 351.41B
Weighted average by Cap. +0.30%+2.14%+28.33%+49.75%

Financials

2026 *2027 *
Net sales 46.72B 54.16B 42.79B 40.44B 74.55B 5,244B 76.43B 510B 199B 2,469B 203B 199B 8,620B 49.58B 57.48B 45.41B 42.91B 79.11B 5,565B 81.1B 541B 211B 2,620B 216B 211B 9,148B
Net income 8.13B 9.43B 7.45B 7.04B 12.98B 913B 13.31B 88.8B 34.58B 430B 35.39B 34.64B 1,501B 8.94B 10.36B 8.19B 7.73B 14.26B 1,003B 14.62B 97.54B 37.99B 472B 38.88B 38.05B 1,649B
Net Debt 12.26B 14.22B 11.23B 10.61B 19.57B 1,376B 20.06B 134B 52.13B 648B 53.35B 52.21B 2,263B 10.4B 12.06B 9.52B 9B 16.59B 1,167B 17.01B 114B 44.2B 549B 45.24B 44.27B 1,919B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
74,846
Date Price Change Volume
26-05-20 76.26 +1.41% 470,438
26-05-19 75.20 +1.16% 2,215,699
26-05-18 74.34 +0.51% 1,958,269
26-05-15 73.96 +0.98% 2,219,071
26-05-14 73.24 +0.72% 1,394,965
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
75.20EUR
Average target price
97.10EUR
Spread / Average Target
+29.12%

Quarterly revenue - Rate of surprise